Leerink's Risinger on Eli Lilly downgrade: Triggered by disappointing obesity pill results

All right, let's get an analyst take on this with this Eli Liy story and the future of the obesity drug market really hanging in the balance right now. David Risinger is a senior research analyst at Link Partners. He just, by the way, downgraded Eli Liy just today to a market perform from a prior outperform.He also lowered his price target from $944 down to $715. Two very significant and notable moves. David, uh, we just heard Angelica's report.It basically sets you up to take us into some more detail about ...